Sinopharm Group Co Ltd

1099.HK2

Sinopharm Modern to Acquire 51% Stake in Guorui Pharmaceutical for 406 Million Yuan

Sinopharm Modern announced it will acquire a 51% stake in Sinopharm Group Guorui Pharmaceutical for 406 million yuan in cash. The counterparties are Sinopharm Group, Sinopharm Holdings, and Sinopharm Group Medicine. Upon completion, Guorui Pharmaceutical will become a controlled subsidiary of Sinopharm Modern, aiming to eliminate horizontal competition and enrich its product pipeline in areas such as the nervous system and anti-infection. This transaction constitutes a related-party transaction but does not constitute a major asset restructuring, and does not require submission to the shareholders' meeting for review.

1099.HK

央广财经·31dRead more →

1099.HK▼

Sinopharm Accord's first-half 2026 net profit falls 8.97% year on year

Sinopharm Group announced that Sinopharm Accord has released its first-half 2026 performance flash report. Net profit attributable to shareholders of the listed company was 606 million yuan, down 8.97% year on year. During the reporting period, Sinopharm Accord achieved total operating revenue of 36.266 billion yuan, down 1.44% year on year. Operating profit was 834 million yuan, down 9.94%. Total profit was 827 million yuan, down 9.88%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 599 million yuan, down 6.84%. Basic earnings per share were 0.99 yuan, down 9.17%. The weighted average return on equity was 3.21%, down 0.49 percentage points year on year. At the end of the reporting period, the company's total assets were 48.171 billion yuan, down 1.89% year on year. Equity attributable to shareholders of the listed company was 18.873 billion yuan, up 1.42% year on year. Total share capital was 612 million shares, up 10.00% year on year. Net assets per share attributable to shareholders of the listed company were 30.83 yuan, up 1.41% year on year.

000028.CS ▼1099.HK ▼

南方财经网·33dRead more →